LAG3 Recombinant Rabbit mAb (SDT-R159)

產(chǎn)品型號(hào)：S0B2170

更新時(shí)間：2025-10-09

廠商性質(zhì)：生產(chǎn)廠家

訪問量：92

服務(wù)熱線

15855403091

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對(duì)抗體病理/IHC抗體

查看全部產(chǎn)品

癌癥治療新紀(jì)元：ADC藥物如何以“精準(zhǔn)制導(dǎo)+超級(jí)彈頭“改寫抗癌規(guī)則？

成纖維細(xì)胞生長因子21：代謝調(diào)控的新星與治療前沿

GFAP Mouse mAb的應(yīng)用領(lǐng)域有哪些？

產(chǎn)品介紹

LAG3 （CD223） is the third IR to be targeted in the clinic. It is a potential cancer immunotherapeutic target due to its negative regulatory role on T cells and its capacity, in combination with PD1, to mediate a state of exhaustion [PMID: 26018646]. LAG3 up-regulation is required to control overt activation and prevent the onset of autoimmunity. However, persistent antigen exposure in the tumor microenvironment results in sustained LAG3 expression, contributing to a state of exhaustion manifest in impaired proliferation and cytokine production. The exact signaling mechanisms downstream of LAG3 and interplay with other IRs remains largely unknown. However, the striking synergy between LAG3 and PD1 observed in multiple settings, coupled with the contrasting intracellular cytoplasmic domain of LAG3 as compared with other IRs, highlights the potential uniqueness of LAG3. There are now four LAG3-targeted therapies in the clinic with many more in preclinical development [PMID: 28258692].

上一個(gè)：S0B2169S-RMab?B7-H3/CD276 Recombinant Rabbit mAb (SDT-R158)